Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy

2014 ◽  
Vol 22 (10) ◽  
pp. 2851-2859 ◽  
Author(s):  
Rebecca A. Shelby ◽  
Sara N. Edmond ◽  
Anava A. Wren ◽  
Francis J. Keefe ◽  
Jeffrey M. Peppercorn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Endocrine Therapy ◽  
Self Efficacy ◽  
Breast Cancer Survivors ◽  
Well Being ◽  
Physical Symptoms ◽  
Adjuvant Endocrine Therapy ◽  
The Relationship

scholarly journals Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data

2019 ◽  
Vol 25 (5) ◽  
pp. 578-586
Author(s):  
Vanessa B. Sheppard ◽  
Jun He ◽  
Arnethea Sutton ◽  
Lee Cromwell ◽  
Georges Adunlin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Endocrine Therapy ◽  
Breast Cancer Survivors ◽  
Patient Data ◽  
Adjuvant Endocrine Therapy ◽  
Black And White

Associations between morning–evening chronotype, fatigue, and QOL in breast cancer survivors.

2016 ◽  
Vol 34 (3_suppl) ◽  
pp. 246-246 ◽  
Author(s):  
Oxana Palesh ◽  
M. Melissa Packer ◽  
Holly George ◽  
Cheryl Koopman ◽  
Pasquale F. Innominato
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Bright Light ◽  
Well Being ◽  
Cancer Treatments ◽  
Significant Difference ◽  
Morning Type ◽  
The Relationship ◽  
Range Of Values

246 Background: Emerging evidence suggests that circadian disruption is associated with cancer and cancer treatments. Chronotype is defined as a behaviorally manifested preference for a certain timing of sleep and activity. Previous studies have revealed that living out of sync from one’s innate chronotype can have detrimental effects on one’s health. Although there has been research examining the associations between chronotype and health, not much is known about the relationship between chronotype, fatigue, and QOL in cancer survivors. Methods: 68 Breast cancer survivors completed questionnaires to assess their chronotype (Horne-Ostberg), to rate their fatigue (MDASI), and to evaluate their QOL (FACIT). The Horne-Ostberg questionnaire yields a range of values indicating survivors’ preference for early or late activity. The study sample was divided by terciles according to survivors’ “morningness” or “eveningness” preferences (i.e., chronotypes). Results: Morning chronotype was associated with significantly less severe tiredness and drowsiness as well as significantly better physical well-being and fatigue subscale scores as compared to evening chronotype. Tiredness median (M) scores were highest for evening chronotype (M=5.5), moderate for mid-range chronotype (M=4.5), and lowest for morning chronotype (M=3.0), a significant difference (p=0.046). Drowsiness scores were highest for evening chronotype (median=6.0), moderate for mid-range chronotype (M=4.0), and lowest for morning chronotype (M=3.0), p=0.046. The median score for physical well-being was significantly lower for evening compared to morning chronotypes (22.5 vs. 25.0, p=0.038) and morning types reported significantly better health in respect to fatigue compared to evening types (40.5 vs. 35.5, p=0.045). Conclusions: Survivors with early chronotype (early to bed, early to rise) reported less fatigue, drowsiness, and better overall physical well-being. While chronotype is believed to be genetically driven, certain behavioral, pharmacological, and bright light modifications can be used to help patients shift their circadian rhythm towards earlier morning type and may experience improvements in physical well-being.

scholarly journals A Mixed-Methods Study of the Technical Feasibility and Patient Acceptability of a Real-Time Adherence Monitor in Breast Cancer Survivors Taking Adjuvant Endocrine Therapy

2021 ◽  
Author(s):  
Emma E. Bright ◽  
Sarah R. Genung ◽  
Annette L Stanton ◽  
Joanna J. Arch
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Real Time ◽  
Endocrine Therapy ◽  
Breast Cancer Survivors ◽  
Adjuvant Endocrine Therapy ◽  
Mixed Methods Study ◽  
Patient Acceptability ◽  
Anti Cancer ◽  
Adherence Data

Abstract Purpose: Oral anti-cancer medications are increasingly common and endocrine therapies represent the most common oral anti-cancer medications in breast cancer. Adjuvant endocrine therapies reduce the likelihood of recurrence and mortality in the approximately 80% of women diagnosed with hormone-receptor positive breast cancer, thus rendering adherence essential. Real-time medication adherence monitors, such as the Wisepill electronic pillbox, transmit adherence data remotely, allowing for early intervention for non-adherence. However, their feasibility and acceptability have yet to be examined among breast cancer survivors taking endocrine therapies.Methods: This study presents quantitative patient-report and technical support data and qualitative patient acceptability data on using Wisepill, a common real-time adherence monitor, among 88 breast cancer survivors prescribed adjuvant endocrine therapy.Results: This mixed-methods study of a common real-time adherence monitor, among the first in breast cancer survivors taking adjuvant endocrine therapy, demonstrates its technical feasibility and patient acceptability.Conclusion: The use of wireless medication monitors that transmit real-time adherence data are uniquely promising for maximizing the benefits of adjuvant endocrine therapy by allowing for continuous tracking, ongoing communication with oncologic or research teams, and early intervention. This study demonstrates the feasibility and patient acceptability of one such real-time adherence monitor.

scholarly journals Determinants of Weight Gain During Adjuvant Endocrine Therapy and Association of Such Weight Gain With Recurrence in Long-term Breast Cancer Survivors

2018 ◽  
Vol 18 (1) ◽  
pp. e7-e13 ◽  
Author(s):  
Akshara Raghavendra ◽  
Arup K. Sinha ◽  
Janeiro Valle-Goffin ◽  
Yu Shen ◽  
Debu Tripathy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Weight Gain ◽  
Cancer Survivors ◽  
Endocrine Therapy ◽  
Breast Cancer Survivors ◽  
Adjuvant Endocrine Therapy
Sign in / Sign up

Export Citation Format

Share Document